Stephens Inc. AR Has $2 Million Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Stephens Inc. AR increased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 210.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 16,093 shares of the specialty pharmaceutical company's stock after buying an additional 10,916 shares during the quarter. Stephens Inc. AR's holdings in Jazz Pharmaceuticals were worth $1,998,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of JAZZ. Jones Financial Companies Lllp lifted its position in shares of Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock worth $37,000 after buying an additional 130 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth $11,373,000. PNC Financial Services Group Inc. lifted its position in shares of Jazz Pharmaceuticals by 8.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,749 shares of the specialty pharmaceutical company's stock worth $585,000 after buying an additional 374 shares during the last quarter. HighTower Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 27.0% during the 4th quarter. HighTower Advisors LLC now owns 9,648 shares of the specialty pharmaceutical company's stock worth $1,188,000 after buying an additional 2,054 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in Jazz Pharmaceuticals by 96.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 620 shares of the specialty pharmaceutical company's stock valued at $76,000 after purchasing an additional 305 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Trading Down 1.7%

Shares of JAZZ stock traded down $1.99 on Friday, hitting $112.87. The company had a trading volume of 564,041 shares, compared to its average volume of 832,021. The firm has a market cap of $6.83 billion, a P/E ratio of 15.05, a P/E/G ratio of 5.80 and a beta of 0.32. The stock's 50-day moving average is $108.83 and its two-hundred day moving average is $118.35. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.97 and a current ratio of 3.38. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The business had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. During the same period in the prior year, the business earned $2.68 EPS. The company's revenue for the quarter was down .5% on a year-over-year basis. On average, equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the sale, the chief executive officer owned 436,973 shares of the company's stock, valued at $47,031,403.99. This trade represents a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Seamus Mulligan bought 1,621 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were acquired at an average cost of $103.00 per share, with a total value of $166,963.00. Following the purchase, the director directly owned 101,621 shares of the company's stock, valued at $10,466,963. This trade represents a 1.62% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 2,500 shares of company stock valued at $277,930 in the last ninety days. 4.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on JAZZ. Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a research report on Tuesday. They issued a "buy" rating and a $152.00 target price for the company. Robert W. Baird dropped their target price on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Piper Sandler reiterated an "overweight" rating and issued a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Wall Street Zen downgraded Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Finally, Morgan Stanley dropped their target price on Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $181.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.